Cite
HARVARD Citation
Schwabe, C. et al. (2022). Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial. Expert review of clinical immunology. pp. 533-543. [Online].